Thiazolidinedione and cardiovascular risk in type 2 diabetes mellitus

Article Sidebar

PDF
Published: Dec 26, 2008
DOI: https://doi.org/10.18051/UnivMed.2008.v27.183-193 Universa Medicina
Abstract Viewed: 242
PDF Downloaded: 62
Keywords:
Thiazolidinedione heart failure type 2 diabetes ENaC

Main Article Content

Yenny Yenny
Department of Pharmacology, Medical Faculty, Trisakti University

Abstract

Cardiovascular disorders are the most common complications encountered in patients with type 2 diabetes mellitus (DM). The relationship is likely to be multifactorial and may also involve a specific, though ill-defined, diabetic cardiomyopathy. Patients with heart failure accompanied by DM have a reduced cardiac output compared with patients without DM. Thiazolidinediones (TZDs) are agonists of peroxisome proliferator-activated receptor gamma (PPARã) and have beneficial effects in the control of blood glucose and cardiovascular parameters, but the ability of these drugs to induce retention of plasma has to be taken into consideration in prescribing them for patients with DM at high risk of cardiovascular disease. The molecular mechanism of fluid retention by TZDs has not been fully elucidated. Available evidence indicate a possible role of epithelial sodium channels (ENaC) in causing the side effects of TZDs. This paper will discuss the mechanism of ENaC in inducing fluid retention and the management to be applied for anticipating these side effects.

Article Details

How to Cite
Yenny, Y. (2008). Thiazolidinedione and cardiovascular risk in type 2 diabetes mellitus. Universa Medicina, 27(4), 183–193. https://doi.org/10.18051/UnivMed.2008.v27.183-193
Issue
Vol. 27 No. 4 (2008)
Section
Review Article

The journal allows the authors to hold the copyright without restrictions and allow the authors to retain publishing rights without restrictions.

References

Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 2004; 27: 1897-84.

Bell DS. Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 2003; 26: 2433-41.

Thrainsdottir IS, Aspelund T, Thorgeirsson G, Gudnason V, Hardarson T, Malmberg K. The association between glucose abnormalities and heart failure in the population based Reykjavik study. Diabetes Care 2005; 28: 612-6.

Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 1106-18.

Parulkar AA, Pendergrass ML, Granda Ayala R, Lee TR, Fonseca VA. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001; 134: 61-71. [erratum in Ann Intern Med 2001;135: 307].

Mudaliar S, Chang AR, Henry RR. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr Pract 2003; 9: 406-16.

Guan Y, Zhang Y, Davis L, Breyer MD. Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans. Am J Physiol 1997; 273: F1013-22.

Hong G, Lockhart A, Davis B, Rahmoune H, Baker S, Ye L, et al. PPARgamma activation enhances cell surface ENaCalpha via up-regulation of SGK1 in human collecting duct cell. FASEB J 2003; 17: 1966-8.

Chen L, Yang B, McNulty JA, Clifton LG, Binz JG, Grimes AM. GI262570, a peroxisome proliferator-activated receptor g agonist, changes electrolytes and water reabsorbtion from the distal nephron in rats. J Pharmacol Exp Ther 2005; 312: 718-25.

Karalliedde J, Buckingham R, Starkie M, Lorand D, Stewart M, Viberti G, et al., for the Rosiglitazone Fluid Retention Study Group. Effect of various diuretic treatments on rosiglitazone induced fluid retention. J Am Soc Nephrol 2006; 17: 3482-90.

Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 56: 2457-71.

Sing S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007; 298: 1189-95.

Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, et al. RECORD Study Group Rosiglitazone evaluated for cardiovascular outcomes: an interim analysis. N Engl J Med 2007; 370: 1129-36.

Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROspective Pioglitazone Clinical Trial in MacroVascular Events Study (PROactive Study): a randomized controlled trial. Lancet 2005; 366: 1279-89.

Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM, et al. The effect of pioglitazone on recurrent myocardial infarction in 2.445 patients with type 2 diabetes and previous myocardial infarction. Results from the proactive (proactive 05) study. J Am Coll Cardiol 2007; 17: 1772-80.

Wilcox R, Bousser MG, Betteridge DJ, Schernthander G, Pirags V, Kupfer S, et al. Effects of pioglitazone inpatients with type 2 diabetes with or without previous stroke: results from proactive pioglitazone clinical trial in macro vascular events. Stroke 2007; 38: 865-73.

Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007; 298: 1180-8.

Deeg MA, Tan MH. Pioglitazone versus rosiglitazone: effects on lipid, lipoproteins, and apolipoproteins in head to head randomized clinical studies. PPAR Res 2008; Article ID 520465, 6 pages.

U.S. Food and Drug Administration: Rosiglitazone maleate (marketed as Avandia, Avandamet, and Avandary) information 2007. Available at: http://www.fda.gov/cder/drug /infopage/rosiglitazone/default.html. Accessed November 23, 2008.

Steals B, fruchart JC. Therapeutic roles of peroxisome proliferators activated receptor agonists. Diabetes 2005; 54: 2460-70.

Weyer C, Funahashi T, Tanaka S. Hypoadipocectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperisulinemia. J Clin Endocrinol Metab 2002; 86: 1930-5.

Cabrero A, Laguna JC, Vazquez M. Peroxisome proliferators activated receptors and the control of inflammation. Curr Drug Targets Inflamm Allergy 2002; 1: 143-8.

Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, et al. PPAR-gamma ligands increase expression and plasma concentration of adiponection, an adipose-derived protein. Diabetes 2001; 50: 2094-9.

Song J, Knepper MA, Hu X, Verbalis JG, Ecelbarger CA. Rosiglitazone activated renal sodium and water-reabsorptive pathways and lowers blood pressure in normal rats. JPET 2004; 308: 426-33.

Zhang H, Zhang A, Kohan DE, Nelson RD, Gonzalez FJ, Yang T. Collecting duct-specific deletion of peroxisome proliferators activated receptor g blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci USA 2005; 102: 9406-11.

McCormick JA, Bhalla V, Pao AC, Pearce D. SGK1: A rapid aldosterone-induced regulator of renal sodium reabsorption. Physiology 2005; 20: 134-9.

Lang F, Bohmer C, Palmada M, Seebohm G, Strutz-seebohm N, Vallon V. Patho physiological significance of the serum and glucocorticoid inducible kinase isoforms. Physiol Rev 2006; 86: 1151-78.

Firsov D, Gautschi I, Merillat AM, Rossier BC, Schild L. The heterotetrameric architecture of the epithelial sodium channel (ENaC). EMBO J 1998; 17: 344-52.

Agre P, King LS, Yasui M, Guggino WB, Ottersen OP, et al. Aquaporin water channels-from atomic structure to clinical medicine. J Physiol 2002; 542: 3-16.

Knepper MA, Wade JB, Terris J, Ecelbarger CA, Marples D, Mandon B. Renal aquaporins. Kidney Int 1996; 49: 1712-7.

de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003; 362: 316-22.

Ogawa S, Takeuchi K, Ito S. Plasma BNP levels in the treatment of type 2 diabetes with pioglitazone. J Clin Endocrinol Metab 2003; 88: 3993-6.

Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Management of hyperglycemia in type 2 diabetes mellitus: a consensus update regarding the initiation and adjustment of therapy. Update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2008; 31: 173-5.

Erdmann E, Wilcox RG. Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure. Eur Heart J 2008; 29: 12-20.

Nestro RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003; 108; 2941-8.

Hirsch IB, Kelly J, Cooper S. Pulmonary edema associated with troglitazone therapy. Arch Int Med 1999; 159: 1811.

Wilson DR, Honrath U, Sonnenberg H. Thiazid diuretic effect on medullary collecting duct function in the rat. Kidney Int 1983; 23: 711-6.

Shankar SS, Brater C. Loop diuretic: From the Na-K-2Cl transporter to clinical use. Am J Physiol Renal Physiol 2003; 284: F11-21.

Cicoira M, Zanolla L, Rossie A, Golia G, Franceschini L, Brighetti G, et al. Long-term, dose-dependent effects of spironolacton on left ventrikel function and exercise tolerance in patients with chronic renal failure. J Am Coll Cardiol 2002; 40: 304-10.